hPG80 (Circulating Progastrin) as a Blood Biomarker for High-grade Glial Tumors (PROGLIO)

Centre Jean Perrin

Status: Completed

Conditions: Glial Cell Tumors

Treatments: Biological: Blood sample

Study type: Observational

Funder types: Other

Identifiers

NCT05157594

2021-A01907-34

Details and patient eligibility

About

PROGLIO is a French mono-centric study with longitudinal follow-up, in which patients with high grade brain tumors will be included. Blood samples will be taken during their therapeutic follow-up to evaluate plasma concentrations of hPG80 (circulating progastrin).

Enrollment: 30 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Female or male 18 years of age or older.
• Patients with a high grade primary glial tumor (Astrocytoma grade 3; Glioblastoma; Anaplastic Oligodendroglioma)
• Patients scheduled to begin radiation and/or chemotherapy.
• Able to give informed consent to participate in the research.
• Enrolled in a social security plan or beneficiary of such a plan.

Exclusion criteria

• Patient under guardianship or curatorship
• Psychological disorder (cognitive disorders, vigilance disorders, etc.) or social reasons (deprivation of liberty by judicial or administrative decision) or geographical reasons that could compromise the medical follow-up of the trial.
• Refusal to participate.
• Pregnant or breastfeeding woman.

Trial design

30 participants in 1 patient group

All patients

Description:

A fasting blood sample will be taken on the day of the beginning and the day of the end of the radiotherapy and during the adjuvant chemotherapy (every 3 cycles). A follow-up will be performed for 9 months, with a blood sample taken every three months on the day of the follow-up MRI.

Treatment:

Biological: Blood sample